Login to Your Account



NEWCO NEWS

PERTH, Australia – Australian biotech company Patrys Ltd. is developing an antibody that can enter the cell nucleus. If clinical trials go well, it would be a game-changer, because it would mean that intracellular targets could be accessible to antibodies.

HONG KONG – An 11-year-old Chinese biopharma company has recently entered the public's eye with a $10 million series A funding and a clinical trial approval by the CFDA for its biosimilar etanercept.

Bridgebio Pharma Inc.'s asset hunter Michael Henderson told BioWorld his firm "came a bit late in the game" when attempting to grab a phase II cancer asset that Novartis AG no longer wanted, but officials "burned some nights and weekends" to win.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: